Promising immunotherapeutic targets for treating candidiasis

Front Cell Infect Microbiol. 2024 Feb 9:14:1339501. doi: 10.3389/fcimb.2024.1339501. eCollection 2024.

Abstract

In the last twenty years, there has been a significant increase in invasive fungal infections, which has corresponded with the expanding population of individuals with compromised immune systems. As a result, the mortality rate linked to these infections remains unacceptably high. The currently available antifungal drugs, such as azoles, polyenes, and echinocandins, face limitations in terms of their diversity, the escalating resistance of fungi and the occurrence of significant adverse effects. Consequently, there is an urgent need to develop new antifungal medications. Vaccines and antibodies present a promising avenue for addressing fungal infections due to their targeted antifungal properties and ability to modulate the immune response. This review investigates the structure and function of cell wall proteins, secreted proteins, and functional proteins within C. albicans. Furthermore, it seeks to analyze the current advancements and challenges in macromolecular drugs to identify new targets for the effective management of candidiasis.

Keywords: Candida albicans; antibody; candidiasis; immunotherapy; vaccine.

Publication types

  • Review

MeSH terms

  • Antifungal Agents* / pharmacology
  • Antifungal Agents* / therapeutic use
  • Candida albicans
  • Candidiasis* / drug therapy
  • Candidiasis* / microbiology
  • Drug Resistance, Fungal
  • Echinocandins / pharmacology
  • Humans
  • Immunotherapy

Substances

  • Antifungal Agents
  • Echinocandins

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study received financial support from the National Key Research and Development Program of China (No.2022YFC2303004 and No.2021YFC2300404), the National Natural Science Foundation of China (No. 82020108032), and the Innovation Program of Shanghai Municipal Education Commission (202101070007-E00094).